After being thrown into the whirlwind of her son's third reoccurrence of osteosarcoma recently, Hazlett was told that her family's health insurer, Highmark Blue Cross Blue Shield of Western New York, wouldn't cover the treatment recommended for Harrison, because it's considered experimental, despite it being endorsed by the tumor board at Roswell Park...